REZOLUTE, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
REZOLUTE, INC. (RZLT) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $8.19 million as of 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-09-24
- 2026-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.19M.
- 2025-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.65M.
- 2024-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.28M.
- 2023-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.88M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2026-06-30 | $8.19M 10-K · filed 2026-09-24 | |
| 2025-06-30 | $5.65M 10-K · filed 2026-09-24 | |
| 2024-06-30 | $4.28M 10-K · filed 2025-09-17 | |
| 2023-06-30 | $2.88M 10-K · filed 2024-09-19 | |
| 2022-06-30 | $2.73M 10-K · filed 2023-09-14 | |
| 2021-06-30 | $2.00M 10-K · filed 2022-09-15 | |
| 2020-06-30 | $4.59M 10-K · filed 2021-09-15 | |
| 2019-06-30 | $3.72M 10-K · filed 2020-10-13 | |
| 2018-06-30 | $4.16M 10-K · filed 2019-09-10 | $4.16M 10-K · filed 2018-10-15 |
| 2017-06-30 | $5.11M 10-K · filed 2018-10-15 | |
| 2016-06-30 | $4.40M 10-K · filed 2017-09-22 | |
| 2015-06-30 | $3.08M 10-K · filed 2016-09-28 | |
| 2014-06-30 | $1.68M 10-K · filed 2015-09-28 | |
| 2013-06-30 | $1.27M 10-K · filed 2014-09-30 | |
| 2012-06-30 | $0.00 10-K · filed 2013-09-11 | |
| 2011-12-31 | $0.00 10-K · filed 2013-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |